Ahn 2020.

Study characteristics
Methods	Trial design: case series Type of publication: journal publication Setting: ICU Recruitment dates: 22 February 2020‐29 March 2020 Country: South Korea Language: English Number of centres: 1 Trial registration number: NR Date of trial registration: NR
Participants	Age: 67 and 71 Gender: 1 male, 1 female Ethnicity: NR Number of participants (recruited/allocated/evaluated): 2 Severity of disease: critical Co‐morbidities: case 2 ‐ medical history of hypertension Inclusion criteria: NR Exclusion criteria: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): 400 mg of hydroxychloroquine once daily and lopinavir/ritonavir 400 mg/100 mg twice daily, empirical antibiotics, 4 L/min oxygen flow via nasal cannula, high‐flow oxygen therapy
Interventions	Intervention(s): CP therapy Details of CP: Type of plasma: apheresis plasma, collected with Spectra Optia apheresis system (CMNC software; Spectra Optia IDL Tubing set; Terumo BCT, Lakewood, CO, USA) Volume: 500 mL total Number of doses: 2 Type of antibody test(s) and antibody‐titre(s): anti‐SARS‐CoV‐2 IgG antibody in plasma was measured by ELISA (Novel Coronavirus COVID‐19 IgG ELISA kit; Epitope Diagnostics, San Diego, CA, USA) and OD ratio for IgG Pathogen inactivated: NR RT‐PCR tested: NR Details of donors:  Gender: male HLA and HNA antibody‐negative: NR Severity of disease: pneumonia Timing from recovery from disease: 18‐21 days RT‐PCR tested: yes in 1 participant  Treatment details, including time of plasma therapy (e.g. early stage of disease): administered 7 (case 2) and 22 (case 1) days after admission Comparator: not applicable Concomitant therapy: 400 mg of hydroxychloroquine once daily and lopinavir/ritonavir 400 mg/100 mg twice daily, empirical antibiotics, intubation and mechanical ventilator care, IV methylprednisolone (0.5/1 mg/kg/day daily). Unclear whether these treatments were stopped before plasma transfusion or continuously given Duration of follow‐up: up to 26 days Treatment cross‐overs: not applicable Compliance with assigned treatment: good (all compliant)
Outcomes	Primary study outcome(s): NR Primary review outcomes All‐cause mortality at hospital discharge: reported Time to death: not applicable Secondary review outcomes Number of participants with grade 3 and grade 4 AEs, including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions): reported Number of participants with SAEs: reported Improvement of clinical symptoms, assessed through need for respiratory support at up to 7 days; 8‐15 days; 16‐30 days: reported 30‐day and 90‐day mortality: not applicable Admission to the ICU: reported Length of stay on the ICU: reported Time to discharge from hospital: reported QoL: NR Additional study outcomes: SARS‐CoV‐2 RNA by rRT‐PCR, IL‐6 and CRP, white blood cell count, lymphocyte count, arterial blood gas analysis (PaO2/FiO2), chest X‐ray, overall improvement of clinical symptoms
Notes	Sponsor/funding: funding was provided by: Ministry of Health and Welfare (HI14C1324), Korea HIV/AIDS Cohort Study (2019‐ER5101‐00) COIs: the authors have no potential conflicts of interest to disclose Other: "this study was approved by the IRB of Severance Hospital (IRB No. 4‐2020‐0076) and with participants' written informed consent. The images are published under agreement of the patients."